07:57 AM EDT, 09/19/2025 (MT Newswires) -- KalVista Pharmaceuticals ( KALV ) said Friday that the European Commission and the Swiss Agency for Therapeutic Products, Swissmedic, have approved Ekterly for the treatment of hereditary angioedema in adults and adolescents aged 12 years and older.

The marketing authorizations are based on results from a phase 3 trial which showed that Ekterly achieved significantly faster symptom relief, reduction in attack severity and attack resolution than placebo, the company said.

KalVista expects to initiate its first European launch in Germany in Q4 and launch in Switzerland in the second half of 2026.

KalVista shares were up by nearly 1% in premarket trading.